Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561284 | 0.85 | HTT (0.64) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.85 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL6651446 | 0.84 | NPC1 (0.66) | SMN1; SMN2KMT2AMAPTALDH1A1 | |
| SCHEMBL14586194 | 0.83 | ALOX5 (0.57) | SMN1; SMN2GAAPOLBKMT2AMAPT | |
| SCHEMBL5560476 | 0.82 | ALOX5 (0.57) | SMN1; SMN2GAAPOLBMEN1KMT2A | |
| SCHEMBL14282753 | 0.82 | ALDH1A1 (0.53) | HTTSMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL4625149 | 0.82 | ALOX5 (0.64) | GAAPOLBKMT2AMAPTALDH1A1 | |
| SCHEMBL29954726 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL8005266 | 0.81 | CA12 (0.54) | GAAPOLBMEN1KMT2AMAPT | |
| SCHEMBL29952942 | 0.81 | MEN1 (0.45) | HTTSMN1; SMN2GAAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676926-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS | ThirtyFiveBio Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| WO-2024184650-A1 | BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS. | ThirtyFiveBio Limited (GB) | 2024-09-12 | — | — | WO | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240166665-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4301360-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana Farber Cancer Institute, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-04-09 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183267-B2 | β-lactamase inhibitors and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-02-27 | — | — | US | disclosed |
| US-7119094-B1 | Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade | WARNER-LAMBERT COMPANY (US) | 2006-10-10 | — | — | US | disclosed |
| US-6908919-B2 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
| EP-1448534-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OFTHE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PHARMACIA CORPORATION | 2004-01-08 | — | — | US | disclosed |
| WO-2003029224-A1 | 6-MEMBERED UNSATURATED HETEROCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | HTT 377/4885SMN1; SMN2 4815/4885GAA 3146/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | HTT 377/4885SMN1; SMN2 4815/4885GAA 3146/4885 |
| US-20050043313-A1 | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade | TFPI, TFPI2, PLAT | HTT 1858/4885SMN1; SMN2 4251/4885GAA 1197/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | HTT 2142/4885SMN1; SMN2 1789/4885GAA 792/4885 |
| US-20040006230-A1 | Useful as inhibitors of serine proteases; for therapy and prophylaxis of thrombotic conditions including coronary artery and cerebrovascular diseases | PRSS1, SERPINC1, SERPINE1 | HTT 1940/4885SMN1; SMN2 2680/4885GAA 777/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | HTT 2142/4885SMN1; SMN2 1789/4885GAA 792/4885 |
| US-20090093523-A1 | Tetrazole-substituted aryl amide derivatives and uses thereof | AR, NAT1, TBXA2R | HTT 603/4885SMN1; SMN2 1615/4885GAA 1875/4885 |
| US-20040106626-A1 | 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, TFPI2 | HTT 3961/4885SMN1; SMN2 3698/4885GAA 1836/4885 |
| US-20240166665-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HTT 3980/4885SMN1; SMN2 4608/4885GAA 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.